Get startedLog in
    Picture of Santhera Pharmaceuticals Holding AG logo

    SANN — Santhera Pharmaceuticals Holding AG News Story

    0.000.00%
    ch flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapMomentum Trap
    All News

    Brief: Santhera: NDA For Vamorolone In Duchenne Muscular Dystrophy Accepted And Granted Priority Review By China's NMPA

    Picture of Santhera Pharmaceuticals Holding AG logoSanthera Pharmaceuticals Holding AG
    27/03/2024 06:02
    March 27 (Reuters) - Santhera Pharmaceuticals Holding AG
 SANN.S :
    * ANNOUNCES NDA FOR VAMOROLONE IN DUCHENNE MUSCULAR
DYSTROPHY
ACCEPTED AND GRANTED PRIORITY REVIEW BY CHINA'S NMPA

Further company coverage:  SANN.S 

 (Reporting by Berlin Newsroom)
 ((berlin.newsroom@thomsonreuters.com;))

    Recent news on Santhera Pharmaceuticals Holding AG

    See all news